PARP1 and cancer: Defects in a given repair pathway or inappropriate repair pathway choice can be exploited for synthetic lethal cancer therapy approaches, such as poly(ADP-ribose) polymerase 1 (PARP1) inhibition, which selectively kills HR-deficient cancers (Lord and Ashworth, 2017).